Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors

Vuagnat, Perrine; Auclin, Édouard; Mezquita, Laura; Alfonso, J. Adeva; Tocino, M.R. Vidal; Muñoz, Federico Longo; Dakdouki, Yolla El; Romano, P. Martin; Baldini, Capucine; Varga, Andréa; García‐Carbonero, Rocío; Besse, Benjamin; Massard, Christophe; Hollebecque, Antoine

doi:10.1093/annonc/mdz449.008

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple evidences have highlighted so far the capability of the simple LIPI score, based on the derived neutrophile-to-lymphocyte ratio (dNLR) and LDH, to successfully predict the prognosis of patients with NSCLC treated with immunotherapy [36,37]. LIPI score prognostic ability has been also evaluated in patients with various tumor types treated with ICI, like melanoma, bladder cancer or solid tumors harboring MSI [19,22,36,[38][39][40]. Our study confirms the capability of the LIPI score to successfully stratify patients with solid tumors treated with anti-PD1/PD-L1 in different prognostic subgroups, independently from all main clinicopathological characteristics, a tumor-agnostic fashion, both in terms of PFS and OS.…”

Section: Discussionmentioning

confidence: 99%

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

García-Corbacho

Indacochea

Azucena

et al. 2023

Cancer Immunol Immunother

View full text Add to dashboard Cite

Immune-checkpoint inhibitors (ICI) have revolutionized the therapeutic landscape of cancer. However, optimal patient selection is still an unmet need. One-hundred-forty-six patients with metastatic cancer candidates to ICI at the Hospital Clinic of Barcelona Clinical Trials Unit were prospectively recruited in this observational study. Blood samples were collected at different timepoints, baseline LIPI score calculated and pre-ICI archived tissues retrieved to evaluate PD-L1, tumor-infiltrating lymphocytes (TILs) and PD1 mRNA levels. Tumor assessments were centrally reviewed by RECIST 1.1 criteria. Associations with overall response rates (ORR), durable clinical benefit (DCB), progression-free survival (PFS) and overall survival (OS) were performed with univariable/multivariable logistic and Cox regressions, where appropriate. At a median follow-up of 26.9 months, median PFS and OS were 2.7 and 12.9 months. Response rates were 17.8% with duration of response (DOR) of 4.4 months. LIPI score was independently associated with PFS (p = 0.025) and OS (p < 0.001). Immunotherapy-naïve status was independently associated with better PFS (p = 0.005). Time-to-best response (TTBR) and ORR (p < 0.001 both) were associated with better OS at univariate analysis. PFS and DOR were moderately correlated with OS (p < 0.001 both). A PD-L1 10% cut-off detected worse/best responders in terms of ORR (univariate p = 0.011, multivariate p = 0.028) and DCB (univariate p = 0.043). PD1 mRNA levels were strikingly associated to complete responses (p = 0.021). To resume, in our prospective observational pan-cancer study, baseline LIPI score, immunotherapy-naïve status, cancer type and RT before starting ICI were the most relevant clinical factors independently correlated with immunotherapy outcomes. Longer TTBR seemed to associate with better survival, while PD1 mRNA and PD-L1 protein levels might be tumor-agnostic predictive factors of response to ICI and should be furtherly explored.

show abstract

Section: Discussionmentioning

confidence: 99%

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

García-Corbacho

Indacochea

Azucena

et al. 2023

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…Compared to patients in the good prognostic group, those in the intermediate and poor prognostic groups had significantly shorter median PFS and OS when treated with immunotherapy, but no difference was observed among patients receiving chemotherapy [94]. Subsequent studies have confirmed the reliability of the LIPI score in stratifying the prognosis of patients treated with immune-checkpoint inhibitors in several other cancer types, including melanoma, renal cancer, small cell lung carcinoma, head and neck squamous cell carcinoma, urothelial cancer, and triple-negative breast cancer [98][99][100][101][102][103][104][105].…”

Section: Prognostic Value Under Immunotherapymentioning

confidence: 97%

Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond

Mosca,

Nigro,

Pagani

et al. 2023

Biomolecules

View full text Add to dashboard Cite

In the era of immunotherapy, identifying biomarkers of immune system activation has become a high-priority challenge. The blood neutrophil-to-lymphocyte ratio (NLR) has been largely investigated as a biomarker in several cancer types. NLR values have been shown to mirror the tumor-induced inflammatory status and have been demonstrated to be a reliable prognostic tool across stages of disease and therapeutic approaches. When integrated with other biomarkers of response to immunotherapy, such as PD-L1, tumor mutational burden, and tumor-associated immune cells, the NLR may allow to further stratify patients with different likelihoods of deriving a significant clinical benefit. However, despite its accessibility, low cost, and easy interpretation, the NLR is still poorly used as a prognostic tool in daily clinical practice. In this review, we analyze the role of the NLR in defining the relationship between cancer and the immune system, its usefulness in daily clinical practice, and its relationship with other established or emerging biomarkers of immunotherapy outcomes.

show abstract

Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index

et al. 2022

View full text Add to dashboard Cite

Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors

Cited by 4 publications

References 0 publications

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond

Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index

Contact Info

Product

Resources

About